Ultivue Announces Multiple Events for Multiplex Immunofluorescence and Image Analysis Technology in Immuno-Oncology Research at AACR 2022

On April 6, 2022 Ultivue, Inc. an industry leader in multiplexing tools powered by their emerging novel AI-driven image analysis solutions for tissue biomarker studies, reported that data from its FlexVUE formatting for panel design and its newest mouse panel offering for multiplex immunofluorescence (mIF) and spatially resolved biomarker analysis will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Ultivue, APR 6, 2022, View Source [SID1234611530]). The meeting runs April 8th to April 13th in New Orleans, LA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Accepted abstracts during the AACR (Free AACR Whitepaper) conference will feature new data from a streamlined pre-optimized protocol enabling mIF staining on mouse tissue for an improved workflow to investigate T-cell infiltration and additional analysis of the tumor immune microenvironment (TiME) to address the mechanisms of action of immune-related drugs in preclinical syngeneic or GEMM mouse models. The company will also spotlight an early access program for mouse researchers interested in exploring the use of advanced pre-clinical tools to probe the dynamic nature of events occurring in the TiME. Additional abstracts feature the new flexible mIF assays (FlexVUE panels) for discerning relevant distributions of infiltrating immune cells in tumors coupled with UltiStacker software for producing detailed spatial characterizations of specific cell phenotypes. Further datasets showcase the integrated capabilities from Fluidigm and Visiopharm to demonstrate a unique tissue phenotyping workflow combining complementary methods that can unravel the complexity of the tumor microenvironment. Ultivue’s newest workflow to be highlighted at this year’s AACR (Free AACR Whitepaper) will be available through the Company’s CLIA services lab and features a multi-omics analysis that demonstrates the versatility of Ultivue’s InSituPlex technology (ISP) through an integrated workflow for co-detection of protein and RNA on a single tissue section. For more information about the poster presentations and to schedule an onsite meeting with one of our scientists, please refer to View Source

Ultivue will also host their 2nd annual Biomarker Insights Summit on April 8th, 2022, ahead of the annual AACR (Free AACR Whitepaper) meeting. This symposium is designed to promote thought leadership and has been exclusively curated for those working towards the eradication of cancer via immuno-oncology approaches. Scientists from AstraZeneca, Takeda, Gilead, Merck, Bayer and many more will be onsite to share successes and lessons learned to better inform therapeutic efforts and explore how innovative digital pathology insights can provide benefit to clinical trials. For more information, https://biomarkerinsightssummit.com/.